Non-NEDD9 mRNAs with partial complementarity

Non-NEDD9 mRNAs with partial complementarity refers to messenger RNA transcripts that share sequence homology with the NEDD9 (Neural precursor cell expressed, developmentally down-regulated 9) gene, leading to potential off-target interactions with RNA-based therapeutics (Jackson et al., 2003, Nature Biotechnology). NEDD9 is a scaffolding protein involved in integrin-mediated signaling and is a known driver of metastasis in various cancers, such as melanoma and lung adenocarcinoma (UniProt Q14511). When antisense oligonucleotides (ASOs) or siRNAs are designed to target NEDD9, they may inadvertently bind to these non-target mRNAs if there is sufficient partial complementarity, typically involving the seed region in siRNAs or short sequences in ASOs (Bennett & Swayze, 2010, Annual Review of Pharmacology and Toxicology). This unintended binding can trigger the degradation of non-target transcripts via RNase H or the RNA-induced silencing complex (RISC), potentially causing cellular toxicity or confounding experimental results. Identifying and mitigating these off-target effects is a crucial component of the safety profile for any drug candidate targeting the NEDD9 pathway. Consequently, this term does not represent a therapeutic target itself but rather a category of unintended molecular interactions that must be avoided during drug development.

Other names

Off-target mRNAsPartially complementary transcriptsNon-specific mRNA targetsCross-reactive transcripts

Unintended hybridization of RNA-based therapeutics to transcripts with partial sequence homology, leading to degradation via RNase H or the RNA-induced silencing complex (RISC) (Jackson et al., 2003, Nature Biotechnology).